Vidac Pharma Holding Plc Granted Authorization for Clinical Trials

Vidac Pharma Holding Plc received approval from the European Medicines Agency for its inaugural clinical study targeting actinic keratoses (AK). This Phase 2 trial will assess the safety, tolerability, and preliminary efficacy of Vidac Pharma’s treatment in patients with advanced AK lesions. The study includes defined criteria and assessments to ensure reliable data. This marks a key regulatory step for Vidac Pharma, leading to potential future marketing in the EU. The company's shares are recommended as a 'Buy' with a revised target price of EUR 4.20.